Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica iito 600x60px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5562 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 20 21 22 ... 54 55 56  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Computomics–High-Tech Gründerfonds: investment, 201510 HTGF invests into Computomics GmbH 2015-10-27
CRISPR Therapeutics–Vertex: investment, 201510 equity investment $30m as part of 4-year research collaboration 2015-10-26
Vertex–CRISPR Therapeutics: CRISPR technology, 201510– collab research $75m upfront + $30m investm + milestones + royalties to treat genetic diseases 2015-10-26
Neuway Pharma–SEVERAL: investment, 201510 financing round Series A Extension €3.15m led by Wellington Partners bringing Series A to €5.85m 2015-10-22
Neuway Pharma–Wellington Partners: investment, 201510 financing round Series A Extension totalling €3.15m incl €2m from Wellington Partners 2015-10-22
Turgut Ilaç–Merck (DE): biosimilar, 201510– supply multi-year of Provantage End-to-End services for developm + production of biologicals 2015-10-22
Admune Therapeutics–Novartis: investment, 201510 acquisition of Admune by Novartis 2015-10-21
Arvinas–SEVERAL: investment, 201510 financing round Series B $41.6m led by RA Capital Management 2015-10-21
Novartis–Palobiofarma: cancer drug, 201510– license developm + commercialisation of adenosine receptor agonist PBF-509 2015-10-21
Novartis–Xoma: antibody cancer drug, 201510– license developm + commercialisation of TGF-beta antibody programs 2015-10-21
Beyond Batten Disease Foundation–Evotec: drug discovery services, 201510–201712 supply service €na assay developm + use for drug discovery 2015-10-20
Noxxon–SEVERAL: investment, 201510– intention to launch IPO of new shares at Euronext Amsterdam + Paris 2015-10-20
Science 37–Novartis: investment, 201510 financing round Series A totalling $6.5m co-led by Lux Capital + dRx Capital 2015-10-20
Science 37–SEVERAL: investment, 201510 financing round Series A $6.5m co-led by Lux Capital + dRx Capital 2015-10-20
Sigma-Aldrich–Honeywell: research chemicals, 201510–201512 acquisition of Sigma-Aldrich research chemicals business by Honewell 2015-10-20
Zellkraftwerk–Helmholtz: investment, 201510 Ascenion acquires equity position under license agreem with MHH for Switch-Antibodies technology 2015-10-20
Zellkraftwerk–MHH: Switch-Antibodies technology, 201510– license ww excl to Zellkraftwerk GmbH from MHH 2015-10-20
Univ Münster–Thermo Fisher: mass spectrometer, 201510 supply Q Exactive GC hybrid quadrupole-Orbitrap GC-MS/MS system to MEET Battery Research Center 2015-10-19
Basilea–SEVERAL: investment, 201510–201512 proposed public offering in the US + listing at Nasdaq Global Market NOT REALISED 2015-10-16
Pronutria–Bertarelli Group: investment, 201510 investment €na by Gurnet Point Capital completing Pronutria’s Series C financing 2015-10-15
Curetis–SEVERAL: investment, 201510–201511 IPO €40m+€4.3m w 4m+431k new shares at €10/share at Euronext Amsterdam + Brussels 2015-10-14
Luxendo–EMBL: investment, 201510 financing round Series A totalling €6m co-led by EMBL Ventures + LSP 2015-10-14
Luxendo–Life Sciences Partners: investment, 201510 financing round Series A totalling €6m co-led by EMBL Ventures + LSP 2015-10-14
Luxendo–SEVERAL: investment, 201510 financing round Series A €6m co-led by EMBL Ventures + LSP 2015-10-14
Minoryx–Chiesi: investment, 201510 financing round Series A totalling €19.4m incl new investor Chiesi Ventures 2015-10-14
Minoryx–HealthEquity (ES): investment, 201510 financing round Series A totalling €19.4m incl existing investor HealthEquity 2015-10-14
Minoryx–Idinvest Partners: investment, 201510 financing round Series A totalling €19.4m incl new investor Idinvest Partners 2015-10-14
Minoryx–Kurma: investment, 201510 financing round Series A totalling €19.4m incl new investor Kurma Partners 2015-10-14
Minoryx–la Caixa: investment, 201510 financing round Series A totalling €19.4m incl existing investor Caixa Capital Risc 2015-10-14
Minoryx–Roche: investment, 201510 financing round Series A totalling €19.4m incl new investor Roche Venture Fund 2015-10-14
Minoryx–SEVERAL: investment, 201510 financing round Series A €19.4m led by Ysios Capital 2015-10-14
Minoryx–Ysios Capital: investment, 201510 financing round Series A totalling €19.4m incl lead investor Ysios Capital 2015-10-14
Zymeworks–Minapharm: GlymaxX technology, 201510– supply service cell line development for bispecific antibody production applying GlymaxX by ProBioGen 2015-10-14
Boehringer–Philogen: cancer immunotherapy, 201510– collab novel therapeutic concepts for treating AML 2015-10-12
Adheron Therapeutics–Abzena: antibody technology, 201510 existent lead product SDP051 uses Abzena’s Composite Human Antibody technology 2015-10-09
Adheron Therapeutics–Roche: investment, 201510 acquisition $105m upfront cash + $475m milestones 2015-10-09
Affimed–OTHER: investment, 201510 investment €19.2m purchase of 3.3m shares by existing shareholder 2015-10-09
NEO New Oncology–Akampion: public relations, 201510 service existent by Akampion 2015-10-09
NEO New Oncology–SEVERAL: investment, 201510 financing round €5m 2015-10-09
Glycotope–Octapharma: investment, 201510 acquisition of new shares by Octapharma as part of excl license deal 2015-10-08
Octapharma–Glycotope: protein expression technology, 201510– license ww excl to human coagulation factors based on GEX technology 2015-10-08
Merck (US)–Proteros: drug discovery services, 201510– collab €na upfront + research funding + $126m milestones + royalties r+d small mol cancer drug 2015-10-07
Nestlé–Lipotype: lipidomics research, 201510 collab existent use of Lipotype technology for lipid analysis in nutritional research NIHS 2015-10-07
Probiodrug–Rentschler: biological contract manufacturing, 201510– process developm + production of PBD-C06 for pre-clinical + clinical studies 2015-10-07
Marinomed–Austria (govt): investment, 201510 aws Mittelstandsfonds aquires share in Marinomed 2015-10-06
EMBL–IBM: software tools, 201510– supply EMBL deploys Aspera s/w for fast + reliable data transfer 2015-10-05
Fianostics–Sony: fluorescence immunoassay platform, 201510– collab contract manufacturing for MEF assay platform by Sony DADC BioSciences 2015-10-05
Affimed–Aeris Capital: investment, 201510 investment $21.8m for 3.3m shares by existing investor Aeris Capital 2015-10-01
Opti-Lab–Omnilab (DE): investment, 201510 acqu of additonal shares resulting in majority for Omnilab w sole minority owner now Sebastian Haselhun 2015-10-01
Roche–Arvinas: protein degradation drugs, 201510– strategic license multi-year for PROTAC technology to Genentech 2015-10-01
Tizona Therapeutics–Minapharm: GlymaxX technology, 201510– license + contract manufacturing agreem for use of GlymaxX for cancer antibody ProBioGen AG 2015-10-01
United States (govt)–Evotec: compound management, 201510–202009 supply service up to €4.5m to NCI Chemical Biology Consortium 2015-10-01
Sanofi–Pieris: anticalin technology, 2015Q3 collab existent developm of anti-infectives 2015-09-30
Asceneuron–SEVERAL: investment, 201509 financing round Series A CHF30m led by Sofinnova Partners 2015-09-29
Infinity Pharmaceuticals–Max Planck: drug discovery services, 201509– collab in cancer using LDC network with MPG + Helmholtz 2015-09-29
Zinc Ahead–Veeva Systems: investment, 201509 acquisition $130m in cash incl $10m deffered consideration over 3 years 2015-09-29
JnJ–Protectimmun: asthma drug, 201509 collab research JnJ Innovation funding preclinical study at Imperial College Protectimmune lead candidate 2015-09-28
Beijing Clear Biotech–Curetis: Unyvero platform, 201509– distribution excl in Greater China of system + 2 cartridges by BCB 2015-09-25
Nabriva–SEVERAL: investment, 201509 US IPO $92.25m with 9m ADSs at $10.25/ADS at Nasdaq 2015-09-23
Nestlé–AC Immune: Alzheimer test, 201509– collab r+d minimally invasive Tau Dx assay Néstle Institute of Health Sciences 2015-09-23
Zedira–Cardiff Univ: drug discovery, 201509– collab research role of transglutaminase 6 in disease pathway of cerebellar ataxia 2015-09-22
Qiagen–PathoFinder: molecular diagnostics, –201509 collab developm + production of RespiFast RG Panel for Rotor-Gene Q MDx instrument 2015-09-21
Biametrics–SEVERAL: investment, 201509 financing round Series A €3.1m from LBBW Venture + MBG BW + KfW 2015-09-18
French Myopathy Association–Cevec: cell line technology, 201509– license €na to use CAP GT technology for lentivirus cell line developm to Généthon 2015-09-17
Sigma-Aldrich–IROA Technologies: compound library, 201509– distribution ww excl of Mass Spectrometry Metabolite Library of Standards (MSMLS) by Sigma 2015-09-17
Taisho–Polyphor: drug discovery, 201509– collab €na identification of drug candidates using macrocycle platform 2015-09-17
Evolva–SEVERAL: investment, 201509 rights offering CHF57.4m 2015-09-16
Nestlé–Lipid Therapeutics: gastrointestinal drug, 201609– license excl to develop + market LT-02 ww excl Europe + Australia to Nestlé Health Science 2015-09-16
Forbion–SEVERAL: investment, 201509 closing €75m of FCF II Co-invest Fund I incl Coller Capital + Hamilton Lane + KLP 2015-09-10
IAVI–CureVac: mRNA technology, 201509– collab using RNActive technology to deliver HIV immunogens for developm of AIDS vaccines 2015-09-10
Lophius–SEVERAL: investment, 201509 financing round incl VRD GmbH + S-Refit + Wolf Biotech + Bayern Kapital + HTGF 2015-09-10
Venneos–High-Tech Gründerfonds: investment, 201509 seed financing round totalling €1m from HTGF + Max Planck + business angels + family offices 2015-09-10
Venneos–Max Planck: investment, 201509 seed financing round totalling €1m from HTGF + Max Planck + business angels + family offices 2015-09-10
Venneos–SEVERAL: investment, 201509 seed financing round €1m from HTGF + Max Planck + business angels + family offices 2015-09-10
Lophius–High-Tech Gründerfonds: investment, 201509 financing round incl VRD GmbH + S-Refit + Wolf Biotech + Bayern Kapital + HTGF 2015-09-09
Phenomenex–Tecan: automated liquid handling, 201509– collab co-marketing Strata + Strata-X SPE sorbents with Freedom EVO platform 2015-09-08
Pierre Fabre–Addex: CNS drugs, 201509– license option for mGlu3 receptor program to Pierre Fabre Pharmaceuticals 2015-09-08
Lumora–Erba Diagnostics Mannheim: investment, 201509 acquisition of Lumora Ltd renamed Erba Molecular Ltd 2015-09-07
ADC Therapeutics–Instinctif Partners: public relations, 201509 service existent by Instinctif Partners for ADCT 2015-09-02
ADC Therapeutics–SEVERAL: investment, 201509 financing round $80m of ADC Therapeutics incl Auven + AstraZeneca et al 2015-09-02
Baxalta–Novimmune: therapeutic antibodies, 201509– collab r+d €na bispecific antibodies for hemophilia A 2015-09-02
Boehringer–Vectron Biosolutions: gene expression technology, 201509– license non-excl to Vectron technology for use w BI e. coli production system 2015-09-01
Chemie Brunschwig–Link Technologies: reagents, 201509– distribution in Switzerland by Chemie Brunschwig AG 2015-09-01
Intellia Therapeutics–Novartis: investment, 201509 financing round Series B totalling $70m led by OrbiMed + incl co-investor Novartis 2015-09-01
Intellia Therapeutics–SEVERAL: investment, 201509 financing round Series B $70m led by OrbiMed HealthCare Fund Management 2015-09-01
Labfolder–SEVERAL: investment, 201509 financing round € 7-digit led by Charité Biomedical Fund (CBF-1) 2015-09-01
Pfizer–Evotec: drug discovery services, 201509– collab + license agreem 4 years to develop anti-fibrotics 2015-09-01
Hisun Pharmaceutical–IMD Natural Solutions: drug discovery, 201508– collab using IMD natural product lead discovery platform incl €4m investment 2015-08-31
IMD Natural Solutions–Hisun Pharmaceutical: investment, 201508 equity investment €4m as part of collab with Zhejiang Hisun Pharmaceutical Co Ltd 2015-08-31
GSK–LimmaTech Biologics: vaccines, 201508– collab at least 5y using former GlycoVaxyn technology to develop vaccines owned by GSK 2015-08-28
Immatics–Texas (govt): grant, 201508 launch of Immatics US Inc supported by $19.7m grant from CPRIT 2015-08-26
Immatics–Univ Texas: cell therapy, 201508– collab launch joint venture Immatics US Inc with MD Anderson to advance adoptive cellular therapies 2015-08-26
Merus–Novartis: investment, 201508 financing round Series C 1st tranche €na of up to €72.8m round incl existing investor Novartis Venture Fund 2015-08-26
Merus–SEVERAL: investment, 201508 financing round Series C 1st tranche €na of up to €72.8m round 2015-08-26
GeneWorks–Genetrix (ES): genomic reagents, 201508– distribution non-excl Sygnis TruePrime + SunScript RT products in Australia 2015-08-25
MorphoSys–Immatics: cancer immunotherapy, 201508– collab strategic alliance r+d using Xpresident + Ylanthio platforms 2015-08-25
Osthus–Dotmatics: bioinformatics, 201508– collab combined services + product offering for RnD IT for life sciences 2015-08-24
Roche–Lumora: nucleic acid purification, 201508 acquisition €na of Heat Elution purifition technoloyg assets by Roche 2015-08-24
Freudenberg–CMS: legal services, 201508 legal advice by CMS Hasche Sigle on acquisition of Hemoteq AG by Freudenberg Medical Europe GmbH 2015-08-21
Hemoteq–Freudenberg: investment, 201508 acquisition of 74.9% majority share in Hemoteq AG by Freudenberg Medical Europe GmbH 2015-08-21
next pagenext page 1 2 3 ... 20 21 22 ... 54 55 56  next pagenext page



Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica iito 600x60px

» top